Drug intelligence / Profile preview

Vi capsular polysaccharide vaccine

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Vi capsular polysaccharide vaccine (Vi-PS) is a subunit vaccine used to prevent typhoid fever. It contains purified Vi polysaccharide extracted from Salmonella enterica serovar Typhi. Each 0.5 mL dose contains 25 mcg of purified Vi polysaccharide in a phosphate buffered saline solution. The vaccine induces a T cell-independent B cell response and provides protection for approximately 2 years, with an efficacy of about 55% in older children and adults. It is administered as an intramuscular injection and is indicated for use in individuals 2 years of age and older.

Brand names
Typhim ViTypherix
Other names
ViPSVi polysaccharide vaccine
02

Targets

Vi antigen (Vi capsular polysaccharide)

Beyond the preview

Go deeper on Vi capsular polysaccharide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vi capsular polysaccharide vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call